Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (9): 965-969.doi: 10.3969/j.issn.1000-6621.2021.09.018
• Review Articles • Previous Articles Next Articles
QI Xue-ting, LU Yu(), CHEN Xiao-you()
Received:
2021-04-15
Online:
2021-09-10
Published:
2021-09-07
Contact:
LU Yu,CHEN Xiao-you
E-mail:luyu4876@hotmail.com;chenxy1998@hotmail.com
QI Xue-ting, LU Yu, CHEN Xiao-you. Pharmacodynamic characteristics and interaction of new antituberculosis drugs[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 965-969. doi: 10.3969/j.issn.1000-6621.2021.09.018
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.09.018
[1] |
Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med, 2020, 8(1):19. doi: 10.1016/S2213-2600(19)30418-7.
doi: 10.1016/S2213-2600(19)30418-7 URL |
[2] |
邢丽, 田瑞飞, 慕杨娜. 肺结核治疗药物发展现状及合理应用. 临床合理用药杂志, 2020, 13(30):179-181. doi: 10.15887/j.cnki.13-1389/r.2020.30.077.
doi: 10.15887/j.cnki.13-1389/r.2020.30.077 |
[3] |
Caesar LK, Cech NB. Synergy and antagonism in natural product extracts:when 1+1 does not equal 2. Nat Prod Rep, 2019, 36(6):869-888. doi: 10.1039/c9np00011a.
doi: 10.1039/c9np00011a URL |
[4] |
Maltempe FG, Caleffi-Ferracioli KR, do Amaral RCR, et al. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Tuberculosis (Edinb), 2017, 104:24-29. doi: 10.1016/j.tube.2017.02.004.
doi: 10.1016/j.tube.2017.02.004 URL |
[5] |
Foo CS, Lechartier B, Kolly GS, et al. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016, 60(11):6451-6459. doi: 10.1128/AAC.01523-16.
doi: 10.1128/AAC.01523-16 URL |
[6] |
Zhang G, Sheng L, Hegde P, et al. 8-cyanobenzothiazinone analogs with potent antitubercular activity. Medicinal Chemistry Research, 2021, 30(2):449-458. doi: 10.1007/s00044-020-02676-4.
doi: 10.1007/s00044-020-02676-4 URL |
[7] |
Shi J, Lu J, Wen S, et al. In Vitro Activity of PBTZ169 against Multiple Mycobacterium Species. Antimicrob Agents Chemother, 2018, 62(11):e01314-18. doi: 10.1128/AAC.01314-18.
doi: 10.1128/AAC.01314-18 |
[8] |
Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2012, 56(11):5790-5793. doi: 10.1128/AAC.01476-12.
doi: 10.1128/AAC.01476-12 pmid: 22926573 |
[9] |
Makarov V, Manina G, Mikusova K, et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science, 2009, 324(5928):801-804. doi: 10.1126/science.1171583.
doi: 10.1126/science.1171583 pmid: 19299584 |
[10] |
Makarov V, Lechartier B, Zhang M, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med, 2014, 6(3):372-383. doi: 10.1002/emmm.201303575.
doi: 10.1002/emmm.201303575 pmid: 24500695 |
[11] |
Lupien A, Vocat A, Foo CS, et al. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrob Agents Chemother, 2018, 62(11):e00840-18. doi: 10.1128/AAC.00840-18.
doi: 10.1128/AAC.00840-18 |
[12] |
Lechartier B, Cole ST. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2015, 59(8):4457-4463. doi: 10.1128/AAC.00395-15.
doi: 10.1128/AAC.00395-15 pmid: 25987624 |
[13] |
Zhang Q, Liu Y, Tang S, et al. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys, 2013, 67(3):957-963. doi: 10.1007/s12013-013-9589-5.
doi: 10.1007/s12013-013-9589-5 pmid: 23546935 |
[14] |
Chandramohan Y, Padmanaban V, Bethunaickan R, et al. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. J Glob Antimicrob Resist, 2019, 19:348-353. doi: 10.1016/j.jgar.2019.06.013.
doi: S2213-7165(19)30157-2 pmid: 31226332 |
[15] |
Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006, 3(11):e466. doi: 10.1371/journal.pmed.0030466.
doi: 10.1371/journal.pmed.0030466 URL |
[16] |
Lee M, Mok J, Kim DK, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials, 2019, 20(1):57. doi: 10.1186/s13063-018-3053-1.
doi: 10.1186/s13063-018-3053-1 URL |
[17] |
Stephanie F, Saragih M, Tambunan USF. Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment. Pharmaceutics, 2021, 13(5):592. doi: 10.3390/pharmaceutics13050592.
doi: 10.3390/pharmaceutics13050592 URL |
[18] |
Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 2019, 38(7):1293-1296. doi: 10.1007/s10096-019-03551-w.
doi: 10.1007/s10096-019-03551-w URL |
[19] |
Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother, 2011, 55(12):5485-5492. doi: 10.1128/AAC.05293-11.
doi: 10.1128/AAC.05293-11 pmid: 21930883 |
[20] |
Xu J, Li SY, Almeida DV, et al. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother, 2019, 63(5):e00021-19. doi: 10.1128/AAC.00021-19.
doi: 10.1128/AAC.00021-19 |
[21] |
Burki T. BPaL approved for multidrug-resistant tuberculosis. Lancet Infect Dis, 2019, 19(10):1063-1064. doi: 10.1016/S1473-3099(19)30489-X.
doi: 10.1016/S1473-3099(19)30489-X URL |
[22] |
Reddy VM, Dubuisson T, Einck L, et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother, 2012, 67(5):1163-1166. doi: 10.1093/jac/dkr589.
doi: 10.1093/jac/dkr589 URL |
[23] |
Chen P, Gearhart J, Protopopova M, et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother, 2006, 58(2):332-337. doi: 10.1093/jac/dkl227.
doi: 10.1093/jac/dkl227 URL |
[24] |
Lounis N, Vranckx L, Gevers T, et al. In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M.tuberculosis. Med Mal Infect, 2016, 46(4):220-225. doi: 10.1016/j.medmal.2016.04.007.
doi: 10.1016/j.medmal.2016.04.007 URL |
[25] |
Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One, 2012, 7(1):e30479. doi: 10.1371/journal.pone.0030479.
doi: 10.1371/journal.pone.0030479 URL |
[26] |
Lounis N, Guillemont J, Veziris N, et al. R207910 (TMC207): un nouvel antibiotique pour le traitement de la tuberculose [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. Med Mal Infect, 2010, 40(7):383-390. doi: 10.1016/j.medmal.2009.09.007.
doi: 10.1016/j.medmal.2009.09.007 URL |
[27] |
首都医科大学附属北京胸科医院, 中国防痨协会临床试验专业分会, 中国防痨杂志编辑委员会. 氯法齐明治疗结核病的临床应用指南. 中国防痨杂志, 2020, 42(5):409-417. doi: 10.3969/j.issn.1000-6621.2020.05.001.
doi: 10.3969/j.issn.1000-6621.2020.05.001 |
[28] |
Yu W, Chiwala G, Gao Y, et al. TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice. Biomed Pharmacother, 2020, 131:110782. doi: 10.1016/j.biopha.2020.110782.
doi: 10.1016/j.biopha.2020.110782 URL |
[29] |
Lee BY, Clemens DL, Silva A, et al. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One, 2018, 13(11):e0207469. doi: 10.1371/journal.pone.0207469.
doi: 10.1371/journal.pone.0207469 URL |
[30] |
Tyagi S, Ammerman NC, Li SY, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A, 2015, 112(3):869-874. doi: 10.1073/pnas.1416951112.
doi: 10.1073/pnas.1416951112 URL |
[31] |
张叶, 陆宇. 亚胺吩嗪类药物抗结核作用研究进展. 中华结核和呼吸杂志, 2019, 42(2):118-121. doi: 10.3760/cma.j.issn.1001-0939.2019.02.008.
doi: 10.3760/cma.j.issn.1001-0939.2019.02.008 |
[32] |
Zhang D, Liu Y, Zhang C, et al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules, 2014, 19(4):4380-4394. doi: 10.3390/molecules19044380.
doi: 10.3390/molecules19044380 URL |
[33] |
Zhang Y, Zhu H, Fu L, et al. Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob Agents Chemother, 2019, 63(7):e02496-18. doi: 10.1128/AAC.02496-18.
doi: 10.1128/AAC.02496-18 |
[34] |
Wang A, Wang H, Geng Y, et al. Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties. Bioorg Med Chem, 2019, 27(5):813-821. doi: 10.1016/j.bmc.2019.01.022.
doi: 10.1016/j.bmc.2019.01.022 URL |
[35] |
Pethe K, Bifani P, Jang J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med, 2013, 19(9):1157-1160. doi: 10.1038/nm.3262.
doi: 10.1038/nm.3262 URL |
[36] |
Lee BS, Hards K, Engelhart CA, et al. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. EMBO Mol Med, 2021, 13(1):e13207. doi: 10.15252/emmm.202013207.
doi: 10.15252/emmm.202013207 |
[37] |
Yang C, Lei H, Wang D, et al. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis, 2012, 65(3):240-242. doi: 10.7883/yoken.65.240.
doi: 10.7883/yoken.65.240 URL |
[38] |
Zhao W, Zheng M, Wang B, et al. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo. Int J Infect Dis, 2016, 52:23-28. doi: 10.1016/j.ijid.2016.08.027.
doi: 10.1016/j.ijid.2016.08.027 URL |
[39] |
Pieterman ED, Keutzer L, van der Meijden A, et al. Superior efficacy of a bedaquiline, delamanid and linezolid combination regimen in a mouse-TB model. J Infect Dis, 2021: jiab043. doi: 10.1093/infdis/jiab043.
doi: 10.1093/infdis/jiab043 |
[40] |
Yip PC, Kam KM, Lam ET, et al. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013, 42(1):96-97. doi: 10.1016/j.ijantimicag.2013.03.002.
doi: 10.1016/j.ijantimicag.2013.03.002 URL |
[41] |
Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med, 2009, 180(4):371-376. doi: 10.1164/rccm.200904-0611OC.
doi: 10.1164/rccm.200904-0611OC URL |
[42] |
Butler MS, Paterson DL. Antibiotics in the clinical pipeline in October 2019. J Antibiot (Tokyo), 2020, 73(6):329-364. doi: 10.1038/s41429-020-0291-8.
doi: 10.1038/s41429-020-0291-8 URL |
[43] |
Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis, 2018, 18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5.
doi: 10.1016/S1473-3099(18)30110-5 |
[44] |
Jahan S, Davis H, Ashcraft DS, et al. Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase-producing Pseudomonas aeruginosa using Etest and time-kill assay. J Investig Med, 2021, 69(2):371-376. doi: 10.1136/jim-2020-001573.
doi: 10.1136/jim-2020-001573 URL |
[45] |
Dooley KE, Phillips PP, Nahid P, et al. Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev, 2016, 102:116-122. doi: 10.1016/j.addr.2016.01.014.
doi: 10.1016/j.addr.2016.01.014 URL |
[46] |
Wallis RS, Ginindza S, Beattie T, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med,2021,S2213-2600(20)30448-3. doi: 10.1016/S2213-2600(20)30448-3.
doi: 10.1016/S2213-2600(20)30448-3 |
[1] | Chinese Antituberculosis Association. Expert consensus on detection and preventive treatment of latent tuberculosis infection in high-risk population [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 874-878. |
[2] | ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923. |
[3] | LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928. |
[4] | ZHOU Ying-yu, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu, CHEN Xiao-you. Analysis and comparative study on the virulence of several drug-resistant Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 952-960. |
[5] | MA Ting-ting, REN Fei, MA Jin-bao, YANG Han. Resistance of prothionamided and sodium aminosalicylate among isoniazid resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 961-964. |
[6] | CAO Qian-qian, ZHU Bing-dong, NIU Hong-xia. Research progress on recombinant protein subunit vaccine of tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 970-974. |
[7] | XIA Hui, ZHAO Yan-lin. Inspiration of the WHO Updated on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 761-765. |
[8] | HU Yan-jie, GONG Shi-wei, REN Yi. Establishment and evaluation of rapid detection of pyrazinamide resistance of Mycobacterium tuberculosis by probe enzyme digestion using Surveyor [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 813-816. |
[9] | WANG Quan, MA Rui-ying, YANG Ting, ZHANG Ya-li, XU Miao, SA Yu-ling, CHEN Qing-bo. Application value of thermostatic microfluidic system in detection and identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 817-820. |
[10] | WANG Ya-cui, SUN Lin, SHEN A-dong. Application progress of Xpert MTB/RIF Ultra assay in tuberculosis diagnosis in children [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 843-846. |
[11] | FAN Yu-xin, LIU Mei-xiao, CHEN Jing-jing, XU Xin, ZHANG Yu, YUE Peng, CAO Wen-jing, BAO Fu-kai, LIU Ai-hua. Immunomodulatory effect of Mycobacterium tuberculosis lipoarabinomannan and its value on tuberculosis diagnosis [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 847-852. |
[12] | YANG Ting-ting, GAO Qian. The tuberculosis drug-resistance and transmission surveillance network based on whole genome sequencing data [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 645-648. |
[13] | QI Xue, WU Xi-rong, GUO Ya-jie, WANG Yong-hong, MA Qi, CHEN Yu-ying, SUN Lin, SHEN A-dong. Analysis of screening of latent tuberculosis infection in hospitalized children [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 653-658. |
[14] | ZHAO Guo-lian, TAN Xiao-wen, CUI Xiao-li, DANG Li-yun. Analysis of gene polymorphism of Mycobacterium tuberculosis with negative MPT64 antigen in culture filtrate [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 659-663. |
[15] | YI Jun-li, YANG Xin-yu, CHEN Hao, ZHAO Yan-feng, CHEN Shuang-shuang, ZHANG Jie, DING Bei-chuan, DAI Xiao-wei, SUN Shan-hua, WU Wen-qing, LI Chuan-you. Analysis of drug resistance of 1156 clinical isolates of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 677-681. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||